MYGN Myriad Genetics: Utang jangka cendhak perusahaan

Myriad Genetics, Inc. (MYGN) is a recognized authority in preventive oncology, with trust among medical professionals built on the flawless accuracy of its forecasts. This chart on GURU.Markets, illustrating the price evolution of the stock, shows the metric at 0.02. Myriad Genetics, Inc. (MYGN) dominates the genetics niche thanks to exclusive DNA information arrays and MyRisk. High efficiency is maintained through the modernization of automated laboratories operating at maximum capacity.

MYGN Silihan lan utang jangka cendhak perusahaan Myriad Genetics Inc (04.07.2022 - 31.10.2026)

Ringkesan rincian data analitis Myriad (MYGN)

- rega saham lan target rega konsensus:

Rega saham Myriad Genetics|MYGN - Target konsensus

- data kapitalisasi saham perusahaan:

Kapitalisasi pasar Myriad Genetics, Inc.|MYGN - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Myriad Genetics|MYGN - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi marang Aset Bersih myriad.com|MYGN - Nilai Agregat Aset

- rincian utang lan likuiditas:

Total Utang marang Modal Myriad Genetics, Inc.|MYGN - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Myriad Genetics, Inc.|MYGN - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Myriad Genetics, Inc.|MYGN - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Myriad Genetics|Indikator likuiditas cepet myriad.com

- data bathi lan kelipatan valuasi:

MYGN - Penghasilan resik perusahaan

Pambiji fundamental:Myriad Genetics (MYGN)

Produk sing diprodhuksi Myriad Genetics, Inc.

Short-term debt reflects the total obligations of Myriad Genetics, Inc. (MYGN) with a maturity of up to one year. This metric aggregates current loans and accounts payable, determining the immediate pressure on liquidity. By analyzing the volume of short-term accounts payable and loans, an investor assesses the risk of cash flow gaps. For Myriad Genetics, Inc. (MYGN), this indicator is critical when financing new proprietary tests. Payment stability allows the company to effectively resist the expansion of low-cost sequencing platforms.

Pesaing Myriad Genetics, Inc. (MYGN)